RenovoRx, Inc. (RNXT) NASDAQ
0.91
-0.0102(-1.11%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.91
-0.0102(-1.11%)
Currency In USD
Address
4546 El Camino Real
Mountain View, CA 94022
United States of America (the)
Phone
650 284 4433
Website
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
August 26, 2021
| Name | Title | Pay | Year Born |
| Shaun R. Bagai | Chief Executive Officer, Secretary & Director | 814,279 | 1977 |
| Ramtin Agah | Founder, Executive Chairman & Chief Medical Officer | 432,708 | 1966 |
| Ronald Kocak | VP of Finance & Controller | 447,030 | 1958 |
| Leesa Gentry | Chief Clinical Officer | 532,594 | 1970 |
| Ryan Witt | Senior Vice President and Head of Corporate Strategy & Partnerships | 0 | N/A |
| Mark Voll | CFO & Principal Accounting Officer | 0 | 1955 |
| Robert Strasser | Vice President of Operations and R&D | 0 | N/A |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.